ATOSSA THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M |
| Operating expenses | $37.1M | $27.6M | $31.4M | $27.7M | $20.5M |
| Cash from operations | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M |
| Capital expenditure | $23,000 | $19,000 | $14,000 | $27,000 | $9,000 |
| Free cash flow | -$29.8M | -$21.0M | -$21.0M | -$20.8M | -$16.5M |
| Share repurchases | — | $0 | $1.5M | $0 | — |
| Impairments | — | — | — | — | $0 |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M |
Shares outstanding 8.6M · Free float 31.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.